E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036701 |
E.1.2 | Term | Primary insomnia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To evaluate the hypnotic effects on sleep initiation by PSG of a single dose of sublingual zolpidem (Sublinox) versus oral immediate-release zolpidem (Ambien IR) in patients with primary insomnia. The primary endpoint will be Latency to persistent Sleep (LPS) (to test for superiority). Secondary endpoints will be Sleep Onset Latency (SOL) and Latency to Stage 1 (ST1L). - To evaluate the hypnotic effects on sleep continuity by PSG of a single dose of sublingual zolpidem (Sublinox) versus oral immediate-release zolpidem (Ambien IR) in patients with primary insomnia. The following PSG variables will be tested for “at least as good as”: Total Sleep Time (TST), Number and duration of awakenings after sleep onset (WASO). |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate by PSG other visually scored night sleep variables, other latency variables, sleep continuity and sleep architecture of sublingual zolpidem (Sublinox) versus oral immediate-release zolpidem (Ambien IR) in patients with primary insomnia. - To evaluate the patient’s subjective assessment of sleep and next day residual effects of sublingual zolpidem (Sublinox) versus oral immediate-release zolpidem (Ambien IR) in patients with primary insomnia. - To assess tolerability and safety of the study treatments. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subject eligibility is determined based on the following selection criteria:
1. The subject is a male or female aged from18 to 65 years old, inclusive. 2. The subject, if female, is non-pregnant and non-lactating. Females of childbearing potential must use appropriate birth control (barrier methods, hormonal contraceptives, and/or intrauterine devices) for the entire duration of the study. 3. The subject is capable of understanding and willing to comply with the protocol and has signed the informed consent document at screening prior to any study related procedures being performed. 4. Based on sleep history, the subject fulfilled DSM-IV criteria for primary insomnia and had to present the following symptoms: - A complaint is difficulty initiating or maintaining sleep or of nonrestorative sleep that lasts for at least 3 months. - The sleep disturbance (or associated daytime fatigue) causes clinically significant distress or impairment in social, occupational, or other important areas of functioning. - The disturbance does not occur exclusively during the course of Narcolepsy, Breathing-Related Sleep Disorder, Circadian Rhythm Sleep Disorder or Parasomnia. - The subject’s sleep disturbance does not occur exclusively during the course of another mental disorder (eg, Major Depressive Disorder, Generalised Anxiety Disorder, a delirium). - The disturbance is not due to the direct physiological effects of a substance (eg, a drug of abuse, a medication) or a general medical condition. 5. On two consecutive screening nights the subject has a TST < 6.5 h, a duration of WASO > 30 min and a LPS of >= 20 minutes with a mean LPS greater than 30 min. No LPS <20 min and (LPS1+LPS2)/2 >30 min. 6. The subject’s habitual bedtime is between 10:00 p.m. and 1:00 a.m. 7. The subject has a body mass index (BMI) between 18 and 30, inclusive. |
|
E.4 | Principal exclusion criteria |
Any subject who meets any of the following criteria will not qualify for entry into the study:
1. The subject has a known hypersensitivity to zolpidem or related compounds. 2. The subject has participated in any other investigational study and/or taken any investigational drug within 30 days (or five half-lives of the drug prior to screening, whichever is longer) prior to screening. 3. The subject has sleep schedule changes required by employment (eg, shift worker) within three months prior to screening, or has flown across greater than three time zones within seven days prior to screening. 4. The subject has ever had a history of seizures; sleep apnea, chronic obstructive pulmonary disease, restless leg syndrome, periodic leg movement syndrome, schizophrenia, bipolar disorder, mental retardation, cognitive disorder or fibromyalgia. 5. The subject has a history of psychiatric disorder (including anxiety and depression) within the past 6 months. 6. The subject has a history of alcohol abuse or drug abuse within the past 12 months. 7. The subject has a current significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, haematological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication 30 days prior to screening. 8. The subject has used drugs or supplements known to affect sleep/wake function within 1 week (or 5 half lives of the drug, whichever is longer) prior to screening. 9. The subject has used any central nervous system medication within 1 week (or 5 half lives of the drug, whichever is longer) prior to screening. 10. The subject has any clinically important abnormal finding as determined by a medical history, physical examination, ECG, or clinical laboratory tests, as determined by the investigator. 11. The subject has a positive urine drug screen including alcohol at screening or at check-in. 12. The subject (only woman) has a positive pregnancy test (serum hCG) at screening or at check-in. 13. The subject has an apnoea hypopnoea index (per hour of sleep) >10 as seen on PSG, on the first night of the PSG screening. 14. The subject has periodic leg movement (PLM) with arousal index (per hour of sleep) >10 as seen on PSG, on the first night of PSG screening. 15. The subject has any additional condition(s) that in the Investigator’s opinion would: a) affect sleep/wake function, b) prohibit the subject from completing the study, or c) not be in the best interest of the subject. 16. Alcohol consumption > 40 g alcohol/day (1 glass (25 cl) of beer with 3° of alcohol = 7.5 g, or 1 glass (25 cl) of beer with 6° of alcohol = 15 g, or 1 glass (12.5 cl) of wine with 10° of alcohol = 12 g, or 1 glass (4 cl) of aperitif with 42° of alcohol = 17 g). 17. Subjects who smoke more than 10 cigarettes or equivalent/day. Smoking or any use of tobacco will not be allowed while attending the sleep lab. 18. Positive test result on hepatitis B surface antigen, hepatitis C antibody. 19. A positive test for HIV-1, HIV-2. 20. Excessive daily consumption of xanthine containing drinks (i.e > 500 mg/day of caffeine). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Latency to persistent Sleep (LPS) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Overencapsulated Ambien 10 mg tablet |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |